SPRO (Spero Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SPRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Debra Zack | Chief Medical Officer | A | — | — |
| 2026-06-25 | Milind Deshpande | Director | A | — | — |
| 2026-06-25 | Cynthia Smith | Director | A | — | — |
| 2026-06-25 | Kathleen Tregoning | Director | A | — | — |
| 2026-06-25 | John C Jr Pottage | Director | A | — | — |
| 2026-06-25 | FRANK E THOMAS | Director | A | — | — |
| 2026-06-25 | Scott Thomas Jackson | Director | A | — | — |
| 2026-06-25 | PATRICK V.J.J. VINK | Director | A | — | — |
| 2026-05-06 | Esther Rajavelu | See Remarks | Sell | — | — |
| 2026-02-09 | Timothy Keutzer | Chief Operating Officer | Sell | — | — |
| 2026-02-09 | Esther Rajavelu | See Remarks | Sell | — | — |
| 2026-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | — | — |
| 2026-02-04 | Esther Rajavelu | See Remarks | MIXED | — | — |
| 2025-11-12 | Esther Rajavelu | See Remarks | Sell | — | — |
| 2025-09-03 | Ankit Mahadevia | Director | Sell | — | — |
| 2025-09-03 | Timothy Keutzer | Chief Operating Officer | Sell | — | — |
| 2025-06-16 | John C Jr Pottage | Director | A | — | — |
| 2025-06-16 | PATRICK V.J.J. VINK | Director | A | — | — |
| 2025-06-16 | Scott Thomas Jackson | Director | A | — | — |
| 2025-06-16 | Milind Deshpande | Director | A | — | — |
| 2025-06-16 | Kathleen Tregoning | Director | A | — | — |
| 2025-06-16 | Cynthia Smith | Director | A | — | — |
| 2025-06-16 | FRANK E THOMAS | Director | A | — | — |
| 2025-06-16 | Ankit Mahadevia | Director | A | — | — |
| 2025-05-06 | Esther Rajavelu | See Remarks | A | — | — |
| 2025-02-05 | Esther Rajavelu | CFO & CBO | MIXED | — | — |
| 2025-02-05 | Ankit Mahadevia | Director | Sell | — | — |
| 2025-02-05 | Sath Shukla | CEO & President | MIXED | — | — |
| 2025-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | — | — |
| 2024-11-12 | Esther Rajavelu | CFO & CBO | Sell | — | — |
| 2024-08-29 | Timothy Keutzer | Chief Operating Officer | Sell | — | — |
| 2024-08-29 | Ankit Mahadevia | Director | Sell | — | — |
| 2024-08-29 | Sath Shukla | CEO & President | Sell | — | — |
| 2024-08-06 | Sath Shukla | CEO and President | Sell | — | — |
| 2024-05-30 | Milind Deshpande | Director | A | — | — |
| 2024-05-30 | Cynthia Smith | Director | A | — | — |
| 2024-05-30 | PATRICK V.J.J. VINK | Director | A | — | — |
| 2024-05-30 | Scott Thomas Jackson | Director | A | — | — |
| 2024-05-30 | Kathleen Tregoning | Director | A | — | — |
| 2024-05-30 | FRANK E THOMAS | Director | A | — | — |
| 2024-05-30 | Ankit Mahadevia | Director | A | — | — |
| 2024-05-30 | John C Jr Pottage | Director | A | — | — |
| 2024-02-05 | Esther Rajavelu | See Remarks | A | — | — |
| 2024-02-05 | Ankit Mahadevia | Director | Sell | — | — |
| 2024-02-05 | TAMARA L JOSEPH | Chief Legal Officer | MIXED | — | — |
| 2024-02-05 | Sath Shukla | CEO and President | MIXED | — | — |
| 2024-02-05 | KAMAL HAMED | Chief Medical Officer | MIXED | — | — |
| 2024-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | — | — |
| 2024-01-04 | Kathleen Tregoning | Director | A | — | — |
| 2023-11-15 | Esther Rajavelu | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,321,231 | — |
| — | 10%+ Owner | 3,985,719 | — |
| — | Director | 1,979,557 | — |
| — | 10%+ Owner | 1,934,006 | — |
| — | CEO & President | 1,892,216 | — |
| — | Director | 1,425,435 | — |
| — | See Remarks | 986,851 | — |
| — | Director | 877,489 | — |
| — | Chief Medical Officer | 816,192 | — |
| — | Chief Operating Officer | 742,506 | — |
| — | Director | 703,294 | — |
| — | Chief Legal Officer | 562,521 | — |
| — | Chief Medical Officer | 162,311 | — |
| — | Director | 101,454 | — |
| — | Director | 85,000 | — |
| — | Director | 85,000 | — |
| — | Director | 85,000 | — |
| — | Director | 85,000 | — |
| — | Director | 85,000 | — |
| — | Director | 85,000 | — |
| — | Chief Operating Officer | 63,581 | — |
| — | Chief Medical Officer | 62,081 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRO quote page; the site-wide leaderboard is on the insider transactions hub.